Which patient characteristics or clinical factors guide the decision to use Doxorubicin and Trabectedin as first-line treatment for metastatic or unresectable leiomyosarcoma (LMS04)?  

The trial included any patient with Grade 2/3 LMS who present with metastatic disease or unresectable LMS is a candidate for this regimen. Having said that, I always make the patient aware of the high risk of having a grade 3 or higher adverse event. The OS benefit demonstrated in the trial is debat...